Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter For GAVRETO After Consultation With The U.S. FDA For The Treatment Of Adult Patients With Metastatic Rearranged During Transfection
Portfolio Pulse from Benzinga Newsdesk
Rigel Pharmaceuticals has issued a Dear Healthcare Provider letter for GAVRETO after consulting with the FDA about a new safety signal. GAVRETO is used for treating certain types of cancer, including RET fusion-positive non-small cell lung cancer and thyroid cancer.
October 24, 2024 | 8:42 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Rigel Pharmaceuticals has issued a Dear Healthcare Provider letter for GAVRETO after consulting with the FDA about a new safety signal. This could impact the perception and usage of GAVRETO.
The issuance of a Dear Healthcare Provider letter indicates a new safety concern for GAVRETO, which could lead to decreased usage or increased scrutiny from healthcare providers. This may negatively impact Rigel's stock in the short term as investors react to potential changes in GAVRETO's market performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100